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Abstract
IMPORTANCE The Gynecologic Cancer InterGroup (GCIG) recommended that progression-free
survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced ovarian
cancer. Evidence is lacking for the validity of PFS as a surrogate marker of OS in the modern era of
different treatment types.
OBJECTIVE To evaluate whether PFS is a surrogate end point for OS in patients with advanced
ovarian cancer.
DATA SOURCES In September 2016, a comprehensive search of publications in MEDLINEwas
conducted for randomized clinical trials of systematic treatment in patients with newly diagnosed
ovarian, fallopian tube, or primary peritoneal cancer. The GCIG groups were also queried for
potentially completed but unpublished trials.
STUDY SELECTION Studies with a minimum sample size of 60 patients published since 2001 with
PFS and OS rates available were eligible. Investigational treatments considered included initial,
maintenance, and intensification therapy consisting of agents delivered at a higher dose and/or
frequency compared with that in the control arm.
DATA EXTRACTIONAND SYNTHESIS Using themeta-analytic approach on randomized clinical
trials published from January 1, 2001, through September 25, 2016, correlations between PFS andOS
at the individual level were estimated using the Kendall τ model; between-treatment effects on PFS
andOS at the trial level were estimated using the Plackett copula bivariate (R2)model. Criteria for PFS
surrogacy required R2  0.80 at the trial level. Analysis was performed from January 7 through
March 20, 2019.
MAINOUTCOMES ANDMEASURES Overall survival and PFS based onmeasurement of cancer
antigen 125 levels confirmed by radiological examination results or by combined GCIG criteria.
RESULTS In this meta-analysis of 17 unique randomized trials of standard (n = 7), intensification
(n = 5), andmaintenance (n = 5) chemotherapies or targeted treatments with data from 11 029
unique patients (median age, 58 years [range, 18-88 years]), a high correlation was found between
PFS andOS at the individual level (τ = 0.724; 95%CI, 0.717-0.732), but a low correlationwas found at
the trial level (R2 = 0.24; 95% CI, 0-0.59). Subgroup analyses led to similar results. In the external
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Abstract (continued)
validation, 14 of the 16 hazard ratios for OS in the published reports fell within the 95% prediction
interval from PFS.
CONCLUSIONS ANDRELEVANCE This largemeta-analysis of individual patient data did not
establish PFS as a surrogate end point for OS in first-line treatment of advanced ovarian cancer, but
the analysis was limited by the narrow range of treatment effects observed or by poststudy
treatment. These results suggest that if PFS is chosen as a primary end point, OSmust bemeasured
as a secondary end point.
JAMA Network Open. 2020;3(1):e1918939. doi:10.1001/jamanetworkopen.2019.18939
Introduction
In 2012, approximately 240000womenworldwide were diagnosed with an advanced ovarian,
epithelial, fallopian tube, or primary peritoneal cancer.1 Approximately 75% of women have
Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stage III or IV cancer at diagnosis.
Initial management involves the combination of surgical cytoreduction and systemic chemotherapy.
Carboplatin and paclitaxel constitute the universal standard regimen in themanagement of ovarian
cancer, with a response rate of approximately 65%, median progression-free survival (PFS) ranging
from 16 to 21 months, and median overall survival (OS) ranging from 32 to 57 months.2 Currently, OS
is the criterion standard for the evaluation of treatment, but both OS and PFS have led to drug
approvals by regulatory agencies (the US Food and Drug Administration and EuropeanMedicines
Agency). Progression-free survival gives an earlier assessment of antitumor activity, requires smaller
sample sizes, and is not affected by postprogression therapy. The Gynecologic Cancer InterGroup
(GCIG)3 recommended that PFS can serve as a primary end point instead of OS, provided that
secondary end points, such as quality of life, support the superiority of the investigated treatment.
Evidence of the validity of PFS as a surrogate marker of OS in the modern era of different treatment
types is lacking. In 2009, Buyse4 showed that PFS was a good surrogate marker of OS in ovarian
cancer, but that study was limited to 4 trials that investigated standard cytotoxic regimens
(cyclophosphamide plus cisplatin vs cyclophosphamide plus doxorubicin hydrochloride [Adriamycin]
plus cisplatin) and used the older World Health Organization definition of progression. A correlation
at the individual level measured by a Kendall τ of 0.84 (95% CI, 0.83-0.85) and at the group level
measured by a Pearson correlation of 0.95 (95% CI, 0.82-1.00) was found. In these trials, treatment
effect on PFS was associated with treatment effect on OS.
Since then, novel targeted therapies have been introduced, many of which are used as
maintenance therapy. Among the tools to evaluate progression and response to treatment, cancer
antigen 125 (CA125) level is an importantmarker in epithelial ovarian cancer.5 The GCIG integrated the
elevation of CA125 levels into the radiological Response Evaluation Criteria in Solid Tumours (RECIST)
to give a combined definition of progression.6 These combined criteria have never, to our knowledge,
been investigated as anOS surrogate using themeta-analytic approach. Trials use differentmethods
of assessing progression, including clinical or CA125-triggered and regular computed tomographic
(CT) scans. The effect of such different assessment methods on the surrogacy of PFS also has not
been assessed. To formally assess PFSmeasured by RECIST and combined GCIG criteria as a potential
surrogate end point of overall survival, the GCIGmeta-analysis group launched a prospectively
planned pooled analysis of data from 11 029 individual patients (individual patient data [IPD]) and 17
randomized clinical trials of first-line therapy (initial treatment, intensification treatment, or
maintenance treatment) in advanced ovarian cancers.
JAMANetworkOpen | Oncology Progression-Free Survival as a Surrogate End Point of Overall Survival in Ovarian Cancer
JAMA Network Open. 2020;3(1):e1918939. doi:10.1001/jamanetworkopen.2019.18939 (Reprinted) January 10, 2020 2/15
Downloaded From: https://jamanetwork.com/ on 06/08/2020
Methods
This report follows the Preferred Reporting Items for Systematic Reviews andMeta-analyses
(PRISMA)–IPD guidelines for the registration of the protocol, trial identification, data collection and
integrity, assessment of bias, and sensitivity analyses.7 This meta-analysis was registered with
PROSPERO (CRD42017068135). The Ethics Committee of Gustave Roussy Cancer Center, Villejuif,
France, approved this study, and the French data protection authority waived the need for informed
consent for the use of deidentified data.
Trial Selection
In September 2016, a comprehensive search in MEDLINE of publications on advanced ovarian cancer
was conducted. The GCIG groups were queried for potentially completed but unpublished trials.
Eligible trials were randomized clinical trials of systemic treatments in patients with previously
untreated ovarian cancer (or investigating maintenance treatment after first-line systemic
treatment) with a minimum sample size of 60 patients in total and published from January 1, 2001,
through September 25, 2016, with both OS and PFS available. Investigational treatments considered
were initial, maintenance, and intensification therapy that consisted of agents delivered at higher
dose and/or frequency compared with that in the control arm. The investigators of all identified trials
that met the eligibility criteria were contacted for IPD sharing.
Data andOutcomes
We requested data for all individual patients (whether or not they had been included in the primary
analysis) enrolled in each trial. Overall survival was defined as the time from randomization to
all-cause death or the date of the last follow-up used for censoring. Progression-free survival was
defined as the time from randomization to progression or second cancer when this information was
available, time to all-cause death, or the date of the last follow-up used for censoring, whichever
came first. Detailed information on the type of progression was requested; this included the
definition of progression, the radiological and/or clinical evaluation that documented progression,
and serial measurements of CA125 levels. Assessment of progression was grouped into 3main
categories: (1) clinical examination and monitoring of 2 increases of CA125 levels to trigger CT scan
confirmation of progression, (2) radiological monitoring based on RECIST, and (3) both CA125 levels
and radiological assessment in line with the GCIG recommendations. Patients alive without
documented disease progression were censored at the date of last follow-up. All data were centrally
reanalyzed and checked for inconsistencies. In particular, diagnostic tools for randomization quality
were systematically applied.8,9 Analysis of surrogacy was performed January 7 through March
20, 2019.
Statistical Analysis
Forest plots were used to display the hazard ratios (HRs) overall and for individual trials, which were
then used for the evaluation of surrogacy of PFS for OS. The HRs compared the hazard of an event
in patients treated with an investigational regimen with the hazard in patients given the control
treatment. A fixed-effect approach was implemented, and HRs were obtained from the expected
and observed numbers of events. The pooled HRwas then adjusted for the trial. The χ2
heterogeneity test and I2 statistic were used to investigate the overall heterogeneity between
trials.10 Survival curves were estimated with the actuarial-based approach of Peto et al11 to account
for the multiple trials. Evolution of the median survival time was assessed using a linear trend test at
the trial level weighted by the number of events. Surrogacy can be evaluated at 2 different levels. At
the individual level, correlation between PFS and OS means that patients with longer PFS are
expected to have longer OS. However, this may only reflect the natural history of the disease,
whatever the treatment is. For the assessment of the trial-level surrogacy, the treatment effect on
PFS was correlated with the treatment effect on OS; in other words, we evaluated howmuch of the
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treatment effect on OS could be predicted from (or explained by) the treatment effect on PFS. We
used the Kendall τ (a rank-correlation coefficient) between PFS and OS to assess surrogacy at the
individual level and the coefficient of determination (corresponding to the explained variation)
between the natural logarithm of the HRs for PFS and OS to assess surrogacy at the trial level.12-15 For
both coefficients, 0 indicates absence of correlation, whereas 1.00 indicates perfect correlation. At
the individual level, the association between the distribution of the true (OS) and surrogate (PFS) end
points was evaluated using a bivariable model based on the Plackett copula combined with trial-
specific Weibull models for PFS and OS.13 The treatment effects on PFS and OSwere obtained from
the bivariate model. The linear association between the 2 treatment effects was estimated, which in
turn provided the coefficient of determination R2 for trial. Following the FLASH (Follicular Lymphoma
Analysis of Surrogacy Hypothesis) initiative16 and a report of childhood acute lymphoblastic
leukemia,17 a surrogate was considered to provide a reliable prediction of the treatment effect on OS
from the PFS HR, when the trial-level correlation exceeded 0.8 and its 95% prediction interval
excluded 0.6. This predefined threshold is arbitrary and served to limit post hoc biases (ie, choice of
the threshold based on the data). Analyses were performed on an intention-to-treat basis (all
patients analyzed in their allocated group irrespective of possible protocol deviations).
Sensitivity and Subpopulation Analysis
Leave-1-out cross-validation was implemented to assess the prediction performance of the
regressionmodel. The validation process was performed on all but 1 trial, and OS HRwas predicted
from the PFS HR for the left-out trial and compared with the observed value. The process was
repeated for each of the 17 trials to identify potential influential trials and investigate the robustness
of the results. Preplanned subgroup analyses investigated the surrogacy measures by definition of
progression, by study design (initial, intensification, ormaintenance treatment), andwithin trials that
used paclitaxel and carboplatin as the control arm.
External Validation
To assess the external validity of our results, we used 16 trials for which we had not been able to
receive IPD from the sponsors. Two of us (X.P. and E.K.) independently extracted the HRs and
confidence intervals for PFS and OS from summary statistics published in these trials.18 The HR on
PFS reported in the publication served to predict HR on OS that we in turn compared with the
published HR on OS. All analyses were done using SAS, version 9.4 (SAS Institute Inc), with macros
developed by Tomasz Burzykowski, PhD, and R, version X, using R surrosurv package, version 1.1.25
(R Project for Statistical Computing).19 Two-tailed P < .05 calculated using the test for heterogeneity
was considered to signify statistical significance. Confidence and prediction intervals were computed
at the 95% level.
Results
Trials’ Descriptions
As illustrated in eFigure 1 in the Supplement, 37 trials were identified from the literature search and
their investigators were contacted. Individual patient data were obtained on 11 029 unique patients
from 17 unique eligible randomized clinical trials with documented OS and PFS.2,20-36 Table 1 lists
the trial-level characteristics of the 17 studies; eTable 1 in the Supplement gives an assessment of the
risk of bias. In 10 trials,20,21,24-29,32,36 carboplatin and taxanes were the comparator. Seven
studies20,22,24,26,28,32,36 investigated initial treatment; 5 studies,21,24,25,30,33 intensification
treatment; and 5 studies,23,27,31,34,35 maintenance treatment. Four trials testedmolecularly targeted
treatments.23,27,31,34 A total of 10 trials21-23,25,26,30,33,34,36 used CA125 levels to trigger follow-up CT
scans after an initial increase in the biomarker. Six trials24,27-29,31,35 used the GCIG criteria (1
multinational trial used both), and 2 trials20,32 used CT scan only. Data on both end points were
available for all 11 029 patients, of whom 7436 experienced progression and 5138 died during
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follow-up. Detailed information about patients’ characteristics by allocated treatment arm and
median follow-up are provided in eTable 2 in the Supplement. Median patient age was 58 years
(range, 18-88 years); 5990 (54.3%) had Eastern Cooperative Oncology Group performance status of
Table 1. Trial Characteristics
Source (Trial Name)
Investigational Regimen
(No. of Patients)
Standard Regimen
(No. of Patients)
Assessment of
Progressiona
Standard
Arm, No. of
Patients
Investigational
Arm, No. of
Patients
First
Inclusion
Date
Follow-up,
Median
(IQR), y
Median
OS, y
Median
PFS, y
Maintenance
Vergote et al,34 2014
(EORTC-55041)
Erlotinib hydrochloride
(420)
Observation (415) Clinical CA125
level
(confirmation
with CT)
412 419 2005 4.3
(3.8-4.8)
4.6 1.0
Hirte et al,23 2006
(CCTG-OV.12)
Tanomastat (122) Placebo (121) Clinical CA125
level
(confirmation
with CT)
121 122 1998 0.9
(0.6-1.3)
NR 0.9
Reyners et al,31 2012
(DoCaCel)
Docetaxel, carboplatin, and
celecoxib (97)
Docetaxel and
carboplatin (99)
GCIG criteria 99 97 2003 4.1
(2.6-5.7)
2.9 1.2
Oza et al,27 2015
(MRC-ICON7)
Bevacizumab (764) Standard
chemotherapy
(764)
GCIG criteria 764 764 2006 4.6
(4.2-5.1)
4.8 1.6
Mannel et al,35 2011
(GOG-0175)
Low-dose paclitaxel (274) Observation (268) GCIG criteria 268 274 1998 11.6
(8.5-13.7)
NR NR
No Maintenance
Aravantinos et al,20 2008
(HECOG-4A99)
Cisplatin, paclitaxel, and
doxorubicin (236)
Paclitaxel and
carboplatin (233)
CT scan 221 225 1999 13.7
(5.4-16.1)
3.2 1.3
Pignata et al, 28 2011
(MITO-2)
Carboplatin and liposomal
doxorubicin (410)
Carboplatin and
paclitaxel (410)
Mixedb 392 396 2003 6.0
(5.0-7.1)
4.7 1.5
Vasey et al,36 2004
(SCOTROC-1)
Docetaxel and carboplatin
(539)
Paclitaxel and
carboplatin (538)
Clinical CA125
level
(confirmation
with CT)
537 538 1998 2.0
(1.6-2.4)
2.9 1.2
Sugiyama et al,32 2016
(JGOG-3017)
Irinotecan hydrochloride
and cisplatin (332)
Carboplatin and
paclitaxel (335)
CT scan 332 329 2009 3.7
(2.8-4.8)
NR NR
Hoskins et al,24 2010
(CCTG-OV.16)
Cisplatin and topotecan
followed by paclitaxel and
carboplatin (409)
Paclitaxel and
carboplatin (410)
GCIG criteria 410 409 2002 8.2
(7.5-8.9)
3.7 1.3
Lindemann et al,26 2012
(NSGO-2012)
Paclitaxel, carboplatin, and
epirubicin hydrochloride
(445)
Paclitaxel and
carboplatin (442)
Clinical CA125
level
(confirmation
with CT)
441 443 1999 5.3
(4.3-5.9)
3.4 1.4
Fruscio et al,22 2008 Cisplatin, ifosfamide, and
paclitaxel (106)
Cisplatin,
epirubicin
hydrochloride, and
paclitaxel (103)
Clinical CA125
level
(confirmation
with CT)
95 97 1997 6.8
(6.2-7.3)
4.7 1.9
Intensification Therapy
Ray-Coquard et al,30 2007
(GINECO-2007)
Cyclophosphamide, erubicin
hydrochloride, cisplatin, and
filgrastim (79)
Cyclophosphamide,
erubicin
hydrochloride, and
cisplatin (85)
Clinical CA125
level
(confirmation
with CT)
85 79 1994 8.6
(6.2-9.9)
2.7 1.2
Pignata et al,29 2014
(MITO-7)
Weekly carboplatin and
paclitaxel (406)
Every 3 wk
carboplatin and
paclitaxel (404)
GCIG criteria 397 393 2008 1.9
(1.4-2.6)
4.0 1.5
Banerjee et al,21 2013
(SCOTROC-4)
Carboplatin dose escalated
(483)
Carboplatin flat
dose (481)
Clinical CA125
level
(confirmation
with CT)
481 483 2005 2.7
(1.7-3.6)
2.7 1.0
Katsumata et al,25 2013
(JGOG-3016)
Dose-dense carboplatin
(317)
Conventional
carboplatin (320)
Clinical CA125
level
(confirmation
with CT)
320 317 2004 6.5
(5.9-7.2)
6.2 2.3
Van der Burg et al,33 2014
(TURBO)
Weekly paclitaxel and
carboplatin (134)
3 Times per week
paclitaxel and
carboplatin (136)
Clinical CA125
level
(confirmation
with CT)
135 134 1998 9.4
(8.4-11.4)
3.6 1.5
Abbreviations: CA125, cancer antigen 125; CT, computed tomography; GCIG, Gynecologic
Cancer InterGroup; IQR, interquartile range; NR, not reached; OS, overall survival; PFS,
progression-free survival.
a “GCIG criteria” indicates that patients were followed up with both serial measurements
of CA125 levels and radiological measurements.
b Progression of Groupe d’investigateurs national des Etudes des Cancers Ovariens
(GINECO) patients was evaluated by CA125 level and confirmed by CT scan, whereas
Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO)
patients were evaluated following the GCIG guidelines.
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0 at enrollment; and 8497 (77.0%) had FIGO stage III or IV disease. eFigure 2 in the Supplement
shows the Peto survival curves for PFS and OS. No statistically significant time trends in themedian
OS and PFS according to the date of the first randomization were detected. The median OS ranged
from 2.7 to 6.2 months and the median PFS ranged from 0.9 to 2.3 months (see Table 1 for median
survival and eFigure 3 in the Supplement for their representation over time). No time trends
according to the date of the first randomization were detected. Figure 1 shows a forest plot of the
treatment effects on OS and PFS for all trials (eFigure 4 in the Supplement gives forest plots grouped
by progression assessment criteria). Overall and at the trial level, the effects of investigational
chemotherapy on PFS and OSwere almost null (HR for PFS, 0.97 [95% CI, 0.93-1.02]; HR for
OS, 0.99 [95% CI, 0.94-1.05]). No heterogeneity across trials was detected for any of the end points
(I2 = 0% [P = .70] for OS and I2 = 0% [P = .60] for PFS) (Figure 1).
Figure 1. Overall and Trial by Trial Treatment Effect onOverall Survival (OS) andProgression-Free Survival (PFS)
Favors
Investigational
Treatment 
Favors
Standard
Treatment 
210.5
HR (95% CI)
Investigational
Treatment, No. 
Events Patients
Standard
Treatment, No. 
Events PatientsStudy
Maintenance
HR
(95% CI)
201 419EORTC-55041 1.05 (0.86-1.29)
318 419EORTC-55041 0.99 (0.85-1.16)
17 122CCTG-OV.12 0.61 (0.34-1.12)
67 122CCTG-OV.12 1.00 (0.71-1.41)
52 97DoCaCel 1.00 (0.69-1.45)
71 97DoCaCel 1.04 (0.75-1.45)
362 764MRC-ICON7 0.99 (0.85-1.14)
554 764MRC-ICON7 0.93 (0.83-1.05)
59 274GOG0175 0.79 (0.56-1.10)
81 274GOG0175 0.78 (0.58-1.04)
No maintenance
154 225HeCOG-4A99 0.94 (0.75-1.17)
174 225HeCOG-4A99 0.86 (0.70-1.06)
195 396MITO-2 0.94 (0.77-1.15)
284 396MITO-2 0.99 (0.84-1.17)
193 538SCOTROC-1 1.15 (0.93-1.41)
343 538SCOTROC-1 0.99 (0.85-1.15)
66 329JGOG-3017 1.04 (0.74-1.47)
93 329JGOG-3017 1.12 (0.84-1.51)
305 409CCTG-OV.16 1.05 (0.89-1.23)
353 409CCTG-OV.16 1.06 (0.92-1.23)
Intensification
61 79GINECO-2007 1.03 (0.73-1.46)
73 79GINECO-2007 1.13 (0.82-1.57)
86 393MITO-7 1.13 (0.83-1.53)
214 393MITO-7 0.93 (0.77-1.13)
232 483SCOTROC-4 1.05 (0.87-1.26)
348 483SCOTROC-4 1.01 (0.87-1.18)
143 317JGOG-3016 0.81 (0.65-1.01)
198 317JGOG-3016 0.78 (0.64-0.94)
105 134TURBO 1.01 (0.77-1.33)
120 134TURBO 1.04 (0.80-1.34)
Cochran heterogeneity test: OS P = .70, I2 = 0%; PFS P = .60, I2 = 0%
272 443NSGO-2012 0.93 (0.79-1.10)
366 443NSGO-2012 1.01 (0.87-1.17)
62 97Fruscio-2008 1.16 (0.80-1.66)
71 97Fruscio-2008 0.92 (0.66-1.27)
184
307
26 
64
63
74
352
526
75
100
221
221
392
392
537
537
332
332
410
410
441
441
95
95
85
85
397
397
481
481
320
320
135
135
412
412
121
121
99
99
764
764
268
268
155
175
200
279
174
343
65
84
300
351
285
361
55
73
68
74
77
218
222 
342
168
225 
104
112
OS
PFS
HR indicates hazard ratio. The size of the squares is
proportional to the sample size of the trial.
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Individual- and Trial-Level Associations
The individual-level association, as measured by the Spearman rank correlation coefficient, reached
0.885 (95% CI, 0.879-0.890). The Kendall τ estimate was 0.724 (95% CI, 0.717-0.732), indicating a
good correlation between PFS andOS; that is, a patient who progresses later ismore likely to survive
longer than a patient who progresses earlier. On the contrary, a very low correlation was noted
between ln(OS HR) and ln(PFS HR) (Figure 2), where ln denotes the natural log transformation of the
HR for each end point. The coefficient of determination, R2 for trial, for the estimated treatment
effects was as low as 0.24 (95% CI, 0-0.59), indicating a low correlation between PFS and OS at the
trial level. The linear regressionmodel from the copula estimates was ln(OS HR) = 0.025 +
[0.67 × ln(PFS HR)]. Standard errors were 0.03 and 0.31 for the intercept and slope, respectively.
This is shown as a straight line in Figure 2, where the x-axis represents the treatment effect on PFS
and the y-axis represents the treatment effect on OS. The shaded area corresponds to the 95%
prediction limits that indicate the range of effect on OS that can be expected for a given effect on
PFS, but owing to the very poor correlation, it remains largely theoretical. Despite large sample sizes,
some trials with similar treatment effect on PFS had a different effect on OS, including PFS HR of
greater than 1.00 together with OSHR of less than 1.00, translating into uncertainty in the prediction.
Sensitivity Analyses
Leave-1-out cross-validation demonstrated the robustness of the results, because we had
consistency between observed and predicted OS treatment effects for each trial based on the PFS
(eFigure 5 in the Supplement). Only 1 strongly influential trial was identified; the OV-12 trial23
investigated tanomastat as maintenance therapy, which was interrupted by Bayer owing to negative
results in other cancer types, and follow-upwas stopped23; progressionwas assessed using CT scans
after initial increase of CA125 levels. Excluding this trial increased the estimate of R2 for trial to a
moderate value of 0.66 (95% CI, 0.40-0.93), more in line with previous results.
SubgroupAnalyses
Subpopulation analyses that separately focused onmaintenance and nonmaintenance trials
confirmed that treatment effect on PFS poorly predicted treatment effect onOS: trial-level surrogacy
was low for maintenance trials (Table 2), with R2 for trial estimates from 0.03 (95% CI, 0-0.35) for
maintenance vs 0.67 (95% CI, 0.36-0.97) for nonmaintenance. The marked difference was mainly
explained by the OV-12 trial in the maintenance subgroup, because the R2 for the trials increased to
Figure 2. Association Between the Hazard Ratio (HR) for the Surrogate
End Point Progression-Free Survival (PFS) and for the True End Point
Overall Survival (OS) by Type of Trial
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Each trial is represented by a bubble of a size proportional to the trial sample
size. The solid straight line is the linear regressionmodel from the copula
estimates that relates the PFS HR to OS HR: ln(OS HR) = 0.025 + [0.67 × ln(PFS
HR)]. The shaded area corresponds to the 95% prediction limits.
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0.78 (95% CI, 0.40-1.00) after exclusion of this trial; the small number of trials in this subgroup
strongly increased the results’ instability. Trial-level correlation was also low (R2 for trial = 0.15; 95%
CI, 0-0.56) in trials that compared investigational treatment with carboplatin and taxanes. In the 6
trials24,27-29,31,35 (4603 patients) that specified GCIG guidelines to assess progression, prediction of
OSHR based on PFSHRwas better (R2 for trial = 0.43; 95%CI, 0.02-1.00) than that in trials that used
CT scan after the initial increase of CA125 level; however, the OV-12 trial23 again reduced the
estimated association between the treatment effects in the trials that used other assessments of
progression.
External Validation
Of the 20 trials in which we could not access the IPD (owing to refusal by the investigators,37-56 no
response to our request, or data declared no longer available), we could extract HRs for 16 of them (8
testing initial treatments and 8 testing maintenance treatments).37-52 None of the trials
demonstrated a statistically significant effect on OS, and only 3 studies43,49,51 reported a statistically
significant reduction of PFS. eTable 3 in the Supplement and Figure 3 display observed OS HR and
PFS HR with 95% CIs, and OS HR predicted from the model of Figure 2. Observed estimates for all
except 2 trials fell within the 95% prediction intervals. However, the intervals are relatively large,
reflecting the uncertainty around the prediction.
Discussion
This pooled analysis was performed on the IPD of 11 029 patients treated in 17 randomized trials of
first-line treatment for advanced ovarian cancer initiated worldwide from 1995 through 2010.
Although PFS was strongly associated with OS at the individual level, we did not find a strong
correlation between the treatment effects on PFS and on OS (ie, HR on PFS did not predict the HR on
OS at the trial level). Low correlation was observed in maintenance and nonmaintenance therapy
trials. Overall, HRs on OS and PFS were close to 1.00, with little heterogeneity among trials whether
maintenance or nonmaintenance treatments were explored. All trials required rigorous response
assessment schedules, with clinical and physical examination, evaluation of CA125 levels, and CT
imaging. At the trial level, PFS assessed by CT scans and CA125 levels following the GCIG guidelines
was moderately correlated with OS in a subgroup of 6 trials.24,27-29,31,35 Nevertheless, the role of
CA125measurements is controversial. No international standard has been established, leading to
variability in calibration, assay design, and reagent specificities,57 and CA125 level is not considered a
stand-alonemarker of progression.
One trial can be seen as an outlier; the tanomastat trial was interrupted by Bayer owing to
negative results in pancreatic and small cell lung cancer trials, resulting in poor follow-up for OS23;
exclusion of this trial led to moderate trial-level associations. Nevertheless, even after exclusion of
this trial, the trial-level correlation was below the predefined threshold. In trials for which we could
Table 2. Overall and Subgroup Analyses of the Surrogacy of Progression-Free Survival for Overall Survival
Analysis
No. of
Trials
No. of
Patients
Individual-Level Correlation,
Kendall τ (95% CI)a
Trial-Level Correlation,
R2 (95% CI)b
Overall 17 11 029 0.724 (0.717-0.732) 0.24 (0-0.59)
Design
Maintenance 5 3340 0.72 (0.71-0.74) 0.03 (0-0.35)
Nonmaintenance 12 7689 0.72 (0.72-0.73) 0.67 (0.36-0.97)
Carboplatin and taxanes
as control
10 7321 0.73 (0.72-0.74) 0.15 (0-0.56)
Progression assessment
CA125 level confirmed
by CT scan
10 5319 0.70 (0.69-0.71) 0.27 (0-0.74)
GCIG criteria 5 4603 0.74 (0.73-0.75) 0.43 (0.02-1.00)
Abbreviations: CA125, cancer antigen 125; CT,
computed tomography; GCIG, Gynecologic Cancer
InterGroup.
a Drawn from the joint Plackett copula model that
quantifies the strength of the association between
progression-free survival and overall survival for a
given patient.
b Indicates the determination coefficient that
quantifies the strength of the association between
the treatment effects on progression-free survival
(progression-free survival hazard ratio) and overall
survival (overall survival hazard ratio).
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not access IPD, no statistically significant treatment effect on OS had been reported. As external
validation, we showed that for those 16 trials, the observed treatment effect (OS HR) fell within the
interval predicted from PFSHR, but the interval was too large to draw accurate predictions onOSHR.
These findings therefore do not support PFS as a substitute for OS in randomized clinical trials:
demonstrating a reduction of PFS HR does not guarantee that a reduction in the hazard of death will
be observed. If PFS is used, the GCIG criteria might be preferable as the means of assessment of
progression.
Previous exploration of surrogacy in trials of first-line treatments in ovarian cancers by Buyse4
found high correlation, but with 4 trials that were split into subunits to increase the number of
treatment effect assessments. More recently, several authors58,59 foundmoderate to high
correlations at the trial level (R2 range, 0.50-0.83) from summary statistics extracted from the
literature. However, unlike IPD, literature-basedmeta-analysis does not enable consistent calculation
of end points or the full use of survival-censored data after quality checks; in addition, estimation of
joint model and hence accounting for the correlated PFS and OS measured in the same patient is
insufficient, leading to potential biases.
The choice of the best measure to quantify the treatment effect is controversial. Although the
HR is probably themost commonly used relativemeasure, its validity is limited by the requirement to
have a proportional hazard (ie, that the HR is constant over time). However, in the clinical trial
International Collaboration on Ovarian Neoplasm (ICON7),27 this assumption did not hold for
bevacizumab as maintenance treatment. The primary analysis was then based on an absolute
measure, the difference in the restrictedmean survival time between the 2 arms. The question of the
surrogacy value of restrictedmean survival times is to be explored in further analyses.
Limitations
Themain limit of our approach is the lack of treatment effects as measured by HR in the collected
trials. Indeed, the lack of heterogeneity in the treatment effects strongly limits our ability to detect an
association between PFS HR and OS HR. The regression line in Figure 2may have beenmore
precisely estimated if HRs had been spread across a large range. However, as shown by the validation
analysis, the trials that were not collected were also negative and followed the same association
between PFS HR and OS HR; additional trials should not strongly modify the conclusions obtained
from this large sample. The treatment of ovarian cancers is well standardized, probably thanks to the
tradition of strong collaborationwithin the GCIG and European Society of Gynecological Oncological
Trial groups (ENGOT). Most trials enrolled large numbers of patients, were multicentric (and many
Figure 3. Observed and Estimated Treatment Effect on Overall Survival
in Validation Trials
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international), shared the same regimen as a control, and collected similar variables. This may explain
the strong homogeneity in the trials’ results; this also supports the generalizability of our findings.
A striking finding is the disappointing treatment effects measured on the PFS and the OS. This
pooled analysis provides a useful benchmark for future trials. We hope that the recent improvements
in PFS seen in a trial of poly–adenosine diphosphate ribose polymerase inhibitors60 translate into
improvements in OS. So far, the combination of carboplatin and paclitaxel remains the standard
chemotherapy backbone for first-line treatment.
Conclusions
Progression-free survival cannot be validated as a strict surrogate of OS for assessing treatment
effects in randomized clinical trials of first-line treatments of advanced ovarian cancers. Our findings
support the GCIG Fifth Ovarian Cancer Consensus Conference statement that OS is the preferred
primary end point for first-line clinical trials with or without a maintenance component,3 but we
recognize the practical challenges and the potential for confounding factors such as crossover and
long postprogression survival. Progression-free survival is an alternative primary end point, but given
that we have not been able to validate it as a surrogate of OS, following the US Food and Drug
Administration and EuropeanMedicines Agency guidances,61,62 it should represent a favorable risk-
benefit association with a large magnitude of the effect or it should contribute to delaying
administration of more toxic therapies as second-line treatments; therefore, if PFS is chosen, OS
must bemeasured as a secondary end point and PFSmust be supported by additional end points,
such as predefined patient-reported outcomes, especially for maintenance therapy.
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